香菇多糖联合化疗治疗中晚期老年NSCLC的临床疗效及安全性研究

Clinical Efficacy and Safety of Lentinan Combined with Chemotherapy for Elderly Patients with Advanced Non-small-cell Lung Cancer Cancer

目的观察香菇多糖联合化疗治疗中晚期老年NSCLC患者的临床疗效及安全性。方法收集2011年1月~2013年12月的病例139例,分为治疗组（n=69）和对照组（n=70）,治疗组予以香菇多糖联合化疗,对照组予以化疗,比较两组间的差异。结果治疗组生活质量改善的有效率为79.7%,高于对照组的64.3%,差异有统计学意义（P〈0.05）。两组的不良反应以血液学毒性、消化道反应为主,其中Ⅲ~Ⅳ度白细胞减少、Ⅱ~Ⅲ度消化道反应的发生率的差异有统计学意义（P〈0.05）。治疗组免疫功能较治疗前提高,差异有统计学意义（P〈0.05）,两组的疾病控制率和无疾病生存期的差异无统计学意义（P〉0.05）。结论香菇多糖可以缓解中晚期老年NSCLC患者的化疗毒副反应、提高其临床耐受性,值得临床推广应用。

Objective To investigate the efficacy and safety of Lentinan combined with chemotherapy in elderly patients with nonsmall-cell lung cancer（NSCLC）. Methods From January 2011 to December 2013, 139 elderly patients with NSCLC in our hospital were divided into treatment group and control group. Patients in the treatment group（n=69） had chemotherapy combined with Lentinan, and patients in the control group（n=70） received chemotherapy only. Then we analyzed and compared the adverse reactions, lymphocytes subsets, NK cells, quality of life and efficacy between the two groups. Results In the treatment group, 79.7% of patients had their life quality improved, while 64.3% had improvement in control group; there were significant difference between the two groups（P〈0.05）. The main adverse reactions of both groups included hematologic toxicities and gastrointestinal reaction, but there were statistical difference between the two groups in incidences of Ⅲ~Ⅳ degree of leucopenia and Ⅱ~Ⅲ degree of gastrointestinal reaction（P〈0.05）. The rates of immuno-cells were improved in the treatment group with statistical difference（P〈0.05）, as compared with those before treatment. There was no statistical difference in disease control rate and progression-free survival between two groups（P〉0.05）. Conclusion Lentinan combined with chemo-regimen could enhance cellular immune function in patients with NSCLC, improve the efficacy of chemotherapy, reduce the side effects and improve quality of life. It deserves application in clinic.